Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Allergy Vaccine Internationally PresentedPositive Phase IIb data on BM32, Biomay’s innovative grass pollen allergy vaccine will be reported next week in hot topic session at major international scientific conference
By: Biomay AG The study *), which was completed in 2014, convincingly provided clinical proof of concept for this first of kind B-cell epitope derived allergy vaccine. It was observed that the Rhinoconjunctivitis Symptom Score (RSS) year was reduced by 25% compared to the placebo (p=0.042, statistically significant) The treatment was safe and very well tolerated. Most side-effects were mild to moderate and resolved within a short period after drug application. Rainer Henning, CEO of Biomay commented: "It is a great honor for Biomay that our study has been selected by the organizers for presentation in one of the most looked-for sessions of this prestigious conference. It is in recognition of the cutting edge clinical science, which has been the result of excellent cooperation between the study investigators and the company. We look forward to discussing the data with opinion leaders in the field of allergy immunotherapy from around the globe at this event." A manuscript for submission to a leading peer reviewed journal in the field of allergy and immunology is also currently in preparation and will be submitted in due course. *) Clinicaltrials.gov identifier NCT01538979 About BM32 and peptide carrier fusion vaccines: BM32 is an innovative grass pollen allergy vaccine based on recombinant peptide carrier technology invented in the lab of Prof. Rudolf Valenta at the Medical University of Vienna. This is a revolutionary concept, which offers potential for a paradigm shift in the treatment of allergies. The peptide carrier fusion proteins are constructed from the immunogenic viral coat protein PreS of the hepatitis B virus (HBV) and peptides from the IgE binding epitopes of the allergens in question; the latter have been engineered to lose their IgE binding capacity. BM32 has been designed to protect patients from the debilitating effects of grass pollen exposure and possibly provide long term cure. The product is very convenient to use for patients and doctors, as only a very small number of subcutaneous applications is needed to achieve efficient desensitization. Based on the same technology platform, additional vaccines targeting different allergies (house dust mite, ragweed, birch and cat dander) are in preclinical development and will be advanced to clinical trials in the near future. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com Contact Biomay AG: Dr. Rainer Henning CEO Biomay AG Vienna Competence Center Lazarettgasse 19 / 1 1090 Vienna, Austria T +43 (0)1 / 79 66 296 - 100 E r.henning@biomay.com W http://www.biomay.com Distribution: PR&D – Public Relations for Research & Education Mariannengasse 8 1090 Vienna, Austria T +43 (0)1 / 505 70 44 E contact@prd.at W http://www.prd.at End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|